Brief: SK Biopharmaceuticals, Eurofarma Enter Into Licensing Agreement For Cenobamate In Latin America
14/07/2022 14:48
July 14 (Reuters) - SK Biopharmaceuticals Co Ltd
326030.KS :
* SK BIOPHARMACEUTICALS, EUROFARMA ENTER INTO LICENSING
AGREEMENT
FOR CENOBAMATE IN LATIN AMERICA
* SK BIOPHARMACEUTICALS CO LTD - IN DEAL, CO WILL RECEIVE AN
UPFRONT PAYMENT OF US$15 MILLION FROM EUROFARMA
* SK BIOPHARMACEUTICALS - IN DEAL, CO ELIGIBLE TO RECEIVE
FUTURE
MILESTONES OF UP TO US$47 MILLION, WITH ROYALTIES ON SALES
GENERATED IN LATIN AMERICA
Source text for Eikon: ID:nPn9DC6CVa
Further company coverage: 326030.KS
Recent news on SK Biopharmaceuticals
See all newsBrief: Sk Biopharmaceuticals Co Signs Licensing-In Contract With 1St Biotherapeutics
US FDA pauses new enrollment in Biohaven's epilepsy drug trials (updated)
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
U.S. STOCKS ON THE MOVE-Meta, Kohl's, J.M. Smucker